4 completed, 2 recruiting, 1 not yet recruiting, 1 withdrawn. 5 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 3, Not yet recruiting 1, Withdrawn 1 |
| Phase 1 | 3 | Recruiting 2, Completed 1 |
Follow Osel, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase II Trial of Pembrolizumab/Chemotherapy With Live Biotherapeutic Product MO-03 in Patients With Early Stage Triple Negative Breast Cancer Live biotherapeutic product: MO-03 1 capsule PO BID - TNBC - Triple-Negative Breast Cancer, TNBC | Phase 2 | Not yet recruiting | Yuan Yuan | 50 | 2026-09-01 | 2026-08-05 |
| Safety Study of MucoCept-CVN Live Biotherapeutic Product L. jensenii 1153-1666, Placebo - HIV -1 Infection | Phase 1 | Recruiting | Craig Cohen, MD, MPH | 12 | 2025-10-06 | 2026-10-16 |
| CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer Biospecimen Collection, Bone Scan, CBM588 Capsules - Advanced Clear Cell Renal Cell Carcinoma, Advanced Renal Cell Carcinoma | Phase 1 | Recruiting | Osel, Inc. | 28 | 2024-06-19 | 2024-05-30 |
| Phase 2 Trial of LACTIN-V in Women at High Risk of HIV Acquisition LACTIN-V, Placebo - Bacterial Vaginosis, HIV Infections | Phase 2 | Completed | University of California, San Francisco | 45 | 2021-05-10 | 2024-08-13 |
| Safety and Clinical Effectiveness of Oral Probiotic MIYA-BM to Prevent Recurrent Clostridium Difficile Infections MIYA-BM Fine Granules (CBM588), Placebo Fine Granules (without CBM588) - Clostridium Difficile Infection | Phase 2 | Withdrawn | Osel, Inc. | 2010-02-01 | 2013-11-11 | |
| Safety and Efficacy Study of Lactobacillus Administered Vaginally in Women With Bacterial Vaginosis LACTIN-V, Placebo control substance - Bacterial Vaginosis | Phase 2 | Completed | Osel, Inc. | 40 | 2008-04-01 | 2009-07-10 |
| Safety Study of Lactobacillus Administered Vaginally to Healthy Women Low dose LACTIN-V applicator, Medium dose LACTIN-V applicator, High dose LACTIN-V applicator - Bacterial Vaginosis | Phase 1 | Completed | Osel, Inc. | 12 | 2007-11-01 | 2020-09-16 |
| Intravaginal LACTIN-V for Prevention of Recurrent Urinary Tract Infection Lactin-V, Placebo - Urinary Tract Infection | Phase 2 | Completed | University of Washington | 100 | 2006-03-01 | 2023-04-14 |
Vaginosis, Bacterial (3) · Bacterial Infections (1) · Carcinoma, Renal Cell (1) · Clear-cell metastatic renal cell carcinoma (1) · Clostridium Infections (1) · Colitis (1) · Colonic Diseases (1) · Cystitis (1) · Diarrhea (1) · Digestive System Diseases (1) · Enterocolitis (1) · Enterocolitis, Pseudomembranous (1) · Gastroenteritis (1) · Gastrointestinal Diseases (1) · Gram-Positive Bacterial Infections (1)
CTLA-4 Antigen (1) · Control Groups (1) · Ipilimumab (1) · Magnetic Resonance Spectroscopy (1) · Nivolumab (1) · Specimen Handling (1)
United States (6) · South Africa (1)
Craig Cohen, MD, MPH (2) · Alex Chehrazi-Raffle, MD (1) · Anke Hemmerling, MD, MPH, PhD (1) · Ann E Stapleton, MD (1) · Craig R Cohen, MD MPH (1) · Craig R Cohen, MD, MPH (1) · Jin Sun Lee-Bitar, MD (1) · Lynne V. McFarland, Ph.D. (1) · Yuan Yuan, MD (1)
PMID 20644497, PMID 21498386, PMID 21992977, PMID 40194532, PMID 40206350
P01DK053369 (1), P30CA033572 (1), R01HD098978 (1), U01AI186333 (1)